Just because a company is paying someone to pump its stock it doesn’t mean the stock won’t increase substantially in value. Actually the stock could see serious volume and a high level of liquidity, which are two very important things to look for in a penny stock. Just like any other penny stock remember that the rug can be pulled out from underneath you at any point in time. Also watch for the “sell on the news” phenomenon. It can be like clock work with these promoted stocks. The key to promoted stocks is to get in before the crowd and out while the stadium is still sold out. Otherwise you’ll find yourself stuck in the mad rush for the exits.
We can all be jealous about the huge sums these companies dole out to have their stocks pumped. We find ourselves using our hard earned cash to purchase positions while these unscrupulous promoters are simply handed shares/cash just to tout a stock. How hard can that be? Just be wary before buying any penny stock and know whether or not its being promoted, because a promoted stock always has a final death plunge in it, and you surely want to avoid that.
Finally, never believe the hype. Enjoy it, bask in it, but never believe it. Just trade it and you’ll do just fine.
Friday, January 30, 2009
PGYC - And There She Goes!
AS I type this post PGYC hit $.01. It also released news this morning. Remember yesterdays post:
If I had to guess I say PGYC breaks $.01 tomorrow or Monday and the company releases some news soon. I don't know this stock well this is all a hunch, but if you look at the chart you will see what I am talking about. This was a $.04 stock a few months back. I see at least $.01 if not $.02 or better within a week. Just a hunch, as is all of the posts here on this blog.
Lets see where PGYC heads from here. There should be a few more up days left in the gas tank.
PGYC press release today:
Patriot Energy Corporation Taps Into $225 Billion Dollar MarketPatriot Energy Corporation Taps Into $225 Billion Dollar MarketMONTREAL, CANADA -- (Marketwire) -- 01/30/09 -- Patriot Energy Corporation (PINK SHEETS: PGYC) is excited for the opportunity to capture a significant percentage of the $225 billion dollar market with the distribution of the H2O OxygenatorSystem.Tectane Technologies' Business Plan highlights that presently, there are approximately 450 million vehicles in circulation globally. With the average American household owning 1.9 vehicles, The United States of America has the largest vehicle market in the world. As a result, there are a total of 204 million vehicles in the United States of America. Based on a US$500 retail price, the total globalmarket has the potential for a $225 billion retail value for the H2O OxygenatorSystem.Patriot Energy Corporation will market Tectane Technologies' global warming solutions, including but not limited to, the patented AQUAHOL Fuel and Fuel Systemsenabling the injection of water and ethanol into conventional automobile engines."With characteristics such as; flexibility and compatibility with all other technologies including gasoline, ethanol and hybrid cars; the least expensive systemat a retail cost of US$500; applicable to any vehicle, including marine engines; efficient to increase mpg by 25% or more; and effective to reduce CO2 emissions by 25% or more, the H2O Oxygenator System has the potential to become the leading solution as an alternative fuel technology", said Tony Bisante, President and CEO of Patriot Energy Corporation.For more information on TECTANE and its Technologies, please visit the company'swebsite at www.tectane.com and view the documentary on the company and its technologies.www.teltecksolutions.comAll statements in this news release that are other than statements of historicalfacts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.A number of factors may affect our future results and may cause those results todiffer materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the tradingprice and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions
If I had to guess I say PGYC breaks $.01 tomorrow or Monday and the company releases some news soon. I don't know this stock well this is all a hunch, but if you look at the chart you will see what I am talking about. This was a $.04 stock a few months back. I see at least $.01 if not $.02 or better within a week. Just a hunch, as is all of the posts here on this blog.
Lets see where PGYC heads from here. There should be a few more up days left in the gas tank.
PGYC press release today:
Patriot Energy Corporation Taps Into $225 Billion Dollar MarketPatriot Energy Corporation Taps Into $225 Billion Dollar MarketMONTREAL, CANADA -- (Marketwire) -- 01/30/09 -- Patriot Energy Corporation (PINK SHEETS: PGYC) is excited for the opportunity to capture a significant percentage of the $225 billion dollar market with the distribution of the H2O OxygenatorSystem.Tectane Technologies' Business Plan highlights that presently, there are approximately 450 million vehicles in circulation globally. With the average American household owning 1.9 vehicles, The United States of America has the largest vehicle market in the world. As a result, there are a total of 204 million vehicles in the United States of America. Based on a US$500 retail price, the total globalmarket has the potential for a $225 billion retail value for the H2O OxygenatorSystem.Patriot Energy Corporation will market Tectane Technologies' global warming solutions, including but not limited to, the patented AQUAHOL Fuel and Fuel Systemsenabling the injection of water and ethanol into conventional automobile engines."With characteristics such as; flexibility and compatibility with all other technologies including gasoline, ethanol and hybrid cars; the least expensive systemat a retail cost of US$500; applicable to any vehicle, including marine engines; efficient to increase mpg by 25% or more; and effective to reduce CO2 emissions by 25% or more, the H2O Oxygenator System has the potential to become the leading solution as an alternative fuel technology", said Tony Bisante, President and CEO of Patriot Energy Corporation.For more information on TECTANE and its Technologies, please visit the company'swebsite at www.tectane.com and view the documentary on the company and its technologies.www.teltecksolutions.comAll statements in this news release that are other than statements of historicalfacts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.A number of factors may affect our future results and may cause those results todiffer materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the tradingprice and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions
Thursday, January 29, 2009
PGYC - Sometimes it isn't too late to jump on the bandwagon
I usually shy away from stocks that have big runs because I think that their price appreciation has run its course and the stock is ready to sell-off. In penny stock land the sell-off usually is more painful than the rise in price, because supply at the top always wins out over demand on the way down. A penny stock run that lasted weeks or months can come to a crashing halt in a matter of days or even hours as promoters, company insiders, and the like rush to squeeze every last penny out of the stock before its inevitable demise. The defenseless retail investor who bought at the top on a tip from a "friend" is left to average down with his daughters college money thinking the stock will enjoy the type of gains it had in the past. We all know how that story ends.
With that being said there are numerous times where buying at the top can make you a lot of money. Take DLAV for example. DLAV - Dealer Advance was a dormant company and the stock was thinly traded before it ran from $.0004 to $.04+ a year or so ago. The run took at least a week with many, including yours truly, thinking the run was over with each new high the stock made. But it kept going and going and going. And those who sold out early were the ones crying later.
PGYC pops on the Pennystockguru radar because the chart is showing a sizable increase in volume with a nice pop in price. If I had to guess I say PGYC breaks $.01 tomorrow or Monday and the company releases some news soon. I don't know this stock well this is all a hunch, but if you look at the chart you will see what I am talking about. This was a $.04 stock a few months back. I see at least $.01 if not $.02 or better within a week. Just a hunch, as is all of the posts here on this blog.
Happy trading.
With that being said there are numerous times where buying at the top can make you a lot of money. Take DLAV for example. DLAV - Dealer Advance was a dormant company and the stock was thinly traded before it ran from $.0004 to $.04+ a year or so ago. The run took at least a week with many, including yours truly, thinking the run was over with each new high the stock made. But it kept going and going and going. And those who sold out early were the ones crying later.
PGYC pops on the Pennystockguru radar because the chart is showing a sizable increase in volume with a nice pop in price. If I had to guess I say PGYC breaks $.01 tomorrow or Monday and the company releases some news soon. I don't know this stock well this is all a hunch, but if you look at the chart you will see what I am talking about. This was a $.04 stock a few months back. I see at least $.01 if not $.02 or better within a week. Just a hunch, as is all of the posts here on this blog.
Happy trading.
Wednesday, January 28, 2009
FFGO - Start Your Engines
FFGO is now officially off to the races. For anyone who missed the action on FFGO today, you missed out on a high octane fight for shares that began at mid-day and ended at the closing bell. There were three market makers asking to be bought at .0002. This looks like the same scenario that developed in the summer except this time FFGO appears ready to move on less volume. This would be a great sign to shareholders that the stock has less outstanding shares then in prior runs.
A few weeks ago we posted this:
Thursday, January 15, 2009
FFGO - Back In Play?
Some of you may recall our posts regarding FFGO back in the early summer. The stock rose from $.0001 to a high of $.0009 on huge volume and investor interest. The stock has now settled back down to the $.0001 level with no bid.Volume has returned to this stock and one might wonder if a run is in the cards again. With penny stocks, history does tend to repeat itself. FFGO should prove no different in this regard as the SEC filings have returned in earnest. SEC filings are positive when dealing with a $.0001 a stock as long as they don't start with the letter "S". FFGO might fester around the $.0001 area for a few days or a week, but when you least expect it the buyers will far out number the sellers and the stock will take off. FFGO should be a stock worth watching going forward.
Don't say you weren't warned. FFGO looks poised to post another multi 100% run here. We alerted you when there was no bid and the market makers were trying to give shares away. Currently there are 8+ market makers wanting shares at .0001 and only a few selling at .0002.
FFGO could head higher as the week progresses. Keep your eyes on it.
A few weeks ago we posted this:
Thursday, January 15, 2009
FFGO - Back In Play?
Some of you may recall our posts regarding FFGO back in the early summer. The stock rose from $.0001 to a high of $.0009 on huge volume and investor interest. The stock has now settled back down to the $.0001 level with no bid.Volume has returned to this stock and one might wonder if a run is in the cards again. With penny stocks, history does tend to repeat itself. FFGO should prove no different in this regard as the SEC filings have returned in earnest. SEC filings are positive when dealing with a $.0001 a stock as long as they don't start with the letter "S". FFGO might fester around the $.0001 area for a few days or a week, but when you least expect it the buyers will far out number the sellers and the stock will take off. FFGO should be a stock worth watching going forward.
Don't say you weren't warned. FFGO looks poised to post another multi 100% run here. We alerted you when there was no bid and the market makers were trying to give shares away. Currently there are 8+ market makers wanting shares at .0001 and only a few selling at .0002.
FFGO could head higher as the week progresses. Keep your eyes on it.
Tuesday, January 27, 2009
JNIP +71.43% today - Could there be more on the way?
JNIP just another one we nailed for you. Up 71% today on a huge volume day. It just goes to show you that momentum and volume move a stock, as long as the supply stays low. Share registrations can be a hinderance, but in order to sell the stock you need to have a bid. And JNIP was being bid up all day long.
JNIP might have a few more days of upside in it, but I wouldnt tempt fate twice with this one. If you played this pop, pat yourself on the back and move on to the next one.
JNIP might have a few more days of upside in it, but I wouldnt tempt fate twice with this one. If you played this pop, pat yourself on the back and move on to the next one.
Monday, January 26, 2009
JNIP - ready to bust the move?
JNIP -Juniper Group, Inc has been mired in the triple zero range for more than half the year. The drop started not long after its 200-1 reverse split back in July and the price has stabilized down here for the last few months.
Reverse splits are awful for current shareholders, but they do provide a great opportunity down the road. Why? Because a reverse split is like is like a dog that pee's in the house. If it happens once, its likely going to happen again, and again, and again.... until you do something about it, or get rid of the dog.
Most people who purchase a reverse split offender either do it because they like getting pissed on or because they can't get rid of the dog. Here is where the smart money steps in. Wait for the reverse split offender to hit bottom, buy on the bounce volume. Sell before the dogs legs give out. Its an ugly but profitable strategy. Or you can just hold for the next reverse split. The choice is yours.
JNIP may never reverse split again. It may soar to the penny level or more. Anything is possible. But remember every dog has his day. And JNIP will certainly have its day. Just don't be the one left holding the bone.
Reverse splits are awful for current shareholders, but they do provide a great opportunity down the road. Why? Because a reverse split is like is like a dog that pee's in the house. If it happens once, its likely going to happen again, and again, and again.... until you do something about it, or get rid of the dog.
Most people who purchase a reverse split offender either do it because they like getting pissed on or because they can't get rid of the dog. Here is where the smart money steps in. Wait for the reverse split offender to hit bottom, buy on the bounce volume. Sell before the dogs legs give out. Its an ugly but profitable strategy. Or you can just hold for the next reverse split. The choice is yours.
JNIP may never reverse split again. It may soar to the penny level or more. Anything is possible. But remember every dog has his day. And JNIP will certainly have its day. Just don't be the one left holding the bone.
Friday, January 23, 2009
SGLS - What Did We Say? Up 100%+ From Yesterday
Yesterday we posted about SGLS and the unusually high volume on that stock. We said that it could see serious upside from $.0014. You could have grabbed some $.0012's on Friday morning before the stock surged to $.0035 for almost a 200% gain.
The funny thing is that this is likely just the beginning. SGSL filed a 15-12G recently. This was likely done to reduce costs. \This filing indicates that the company is ready to merge. This could explain the recent surge in volume and price. This might also lend another reason to be buying shares before this stock hits .01.
Now that would be some call here. But we've done it before and we'll do it again.
Have a good weekend.
The funny thing is that this is likely just the beginning. SGSL filed a 15-12G recently. This was likely done to reduce costs. \This filing indicates that the company is ready to merge. This could explain the recent surge in volume and price. This might also lend another reason to be buying shares before this stock hits .01.
Now that would be some call here. But we've done it before and we'll do it again.
Have a good weekend.
Thursday, January 22, 2009
SGLS - Signature Leisure Inc. - impending explosion
SGLS closed up 160% on unusually strong volume. The stock has been mired in the .0002 - .0004 range for several weeks. The stock was virtually dormant until the last few trading sessions.
What does this tell you? Usually unexpected volume is met with more unexpected volume, if that makes any sense. Volume is not by chance, someone likely is accumulating shares for an impending run. For anyone who trades penny stocks, unexpected volume is a great indicator of things to come.
SGLS could be poised for a significant run higher here. Look for this stock to receive more investor interest over the next several weeks and the stock to surge from its close today of $.0014.
I don't think $.005 - $.01 is out of the question here. I will revisit this post in a few days to see how my prediction fared. So far I have been fairly accurate.
Keep SGLS on your watch list and if your in the mood for a several 100% profit you might want to listen to this penny stock guru and nab a few SGLS shares for the ride up.
What does this tell you? Usually unexpected volume is met with more unexpected volume, if that makes any sense. Volume is not by chance, someone likely is accumulating shares for an impending run. For anyone who trades penny stocks, unexpected volume is a great indicator of things to come.
SGLS could be poised for a significant run higher here. Look for this stock to receive more investor interest over the next several weeks and the stock to surge from its close today of $.0014.
I don't think $.005 - $.01 is out of the question here. I will revisit this post in a few days to see how my prediction fared. So far I have been fairly accurate.
Keep SGLS on your watch list and if your in the mood for a several 100% profit you might want to listen to this penny stock guru and nab a few SGLS shares for the ride up.
Wednesday, January 21, 2009
MODC - We told you so.
Yesterday we posted about MODC and its potential to perform well over the next few trading sessions:
If the company can hold off on the share certificate printing press this stock could post several more impressive trading days.
Sure enough MODC followed through with another huge percentage gain. Penny stocks seem to be gaining more interest in the New Year. Look for more volume in MODC on Thurday. MODC has soared from $.0002 to $.0024 in two trading sessions. Not even Bernie Madoff can match those gains.
Tuesday, January 20, 2009
MODC - A penny stock wonder
MODC began the trading session on Tuesday with market makers asking $.0002 per share. By the end of the day the stock had recieved record volume and surged several 100% to a high of $.0009.
The company released news mid-day that added dry wood to an already hot fire. If the company can hold off on the share certificate printing press this stock could post several more impressive trading days.
MODC is a stock to keep on your radar going forward. Today's news release from MODC is pasted below.
Modern Technology Corp Announces New Gen-H Hydrogen Injector for Commercial Fleets and Rolls Out 2009 Business Plan
Tuesday January 20, 2009, 1:35 pm EST
OXFORD, MS--(MARKET WIRE)--Jan 20, 2009 -- Modern Technology Corporation (Other OTC:MODC.PK - News) announced today its new Gen-H On-Demand Hydrogen Generator for Commercial Fleet Trucks. This newly designed system will be available for fleet orders March 1, 2009.
The Gen-H system delivers increased fuel economy between 10% and 50% and significantly reduces or eliminates truck exhaust emissions. The on-demand hydrogen system ensures reliable fuel creation without the hazard of hydrogen storage. The Gen-H system creates fuel from water and delivers pure hydrogen and oxygen directly to the vehicle's engine.
The fuel savings realized by the fleet rapidly pays for the system. The reduced or eliminated emissions levels ensure continuing regulatory compliance.
New applications for the Gen-H water-as-fuel and hydrogen-based fuel systems are under constant development and will be announced accordingly.
As part of MODC's roll-out plan for 2009, announcements will be soon made regarding:
-- Pro forma profitable revenues for the period ending September 30, 2008
were $24,050,155. Year-End 2008 revenues will be soon released.
-- Revenue projections for 2009 will be announced.
-- International distribution agreements for the Gen-H Hydrogen Injector
System will be announced.
-- Additional portfolio acquisitions are under review. Should these
acquisitions occur, revenues will be increased another $5-$15 million
dollars.
-- The company will announce significant advances in its cancer detection
technology.
-- Details on new distribution, management services and new energy-
related initiatives will be released.
About Modern Technology Corp
MODC acquires promising technology companies and related assets to promote their growth and development. The company provides interim management and related services to its portfolio and client companies. It builds revenues and asset value through a model of continuous growth and derives further income from appreciation of its portfolio and licensing or revenue sharing agreements. Web: http://www.moderntechnologycorp.com.
Safe-Harbor
This press release contains statements (such as projections regarding future performance) that are forward-looking as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's web site and prior SEC filings contain various disclosures and RISK FACTORS (incorporated herein by reference) and should be read before any investment decision.
Contact:
Contact:
The company released news mid-day that added dry wood to an already hot fire. If the company can hold off on the share certificate printing press this stock could post several more impressive trading days.
MODC is a stock to keep on your radar going forward. Today's news release from MODC is pasted below.
Modern Technology Corp Announces New Gen-H Hydrogen Injector for Commercial Fleets and Rolls Out 2009 Business Plan
Tuesday January 20, 2009, 1:35 pm EST
OXFORD, MS--(MARKET WIRE)--Jan 20, 2009 -- Modern Technology Corporation (Other OTC:MODC.PK - News) announced today its new Gen-H On-Demand Hydrogen Generator for Commercial Fleet Trucks. This newly designed system will be available for fleet orders March 1, 2009.
The Gen-H system delivers increased fuel economy between 10% and 50% and significantly reduces or eliminates truck exhaust emissions. The on-demand hydrogen system ensures reliable fuel creation without the hazard of hydrogen storage. The Gen-H system creates fuel from water and delivers pure hydrogen and oxygen directly to the vehicle's engine.
The fuel savings realized by the fleet rapidly pays for the system. The reduced or eliminated emissions levels ensure continuing regulatory compliance.
New applications for the Gen-H water-as-fuel and hydrogen-based fuel systems are under constant development and will be announced accordingly.
As part of MODC's roll-out plan for 2009, announcements will be soon made regarding:
-- Pro forma profitable revenues for the period ending September 30, 2008
were $24,050,155. Year-End 2008 revenues will be soon released.
-- Revenue projections for 2009 will be announced.
-- International distribution agreements for the Gen-H Hydrogen Injector
System will be announced.
-- Additional portfolio acquisitions are under review. Should these
acquisitions occur, revenues will be increased another $5-$15 million
dollars.
-- The company will announce significant advances in its cancer detection
technology.
-- Details on new distribution, management services and new energy-
related initiatives will be released.
About Modern Technology Corp
MODC acquires promising technology companies and related assets to promote their growth and development. The company provides interim management and related services to its portfolio and client companies. It builds revenues and asset value through a model of continuous growth and derives further income from appreciation of its portfolio and licensing or revenue sharing agreements. Web: http://www.moderntechnologycorp.com.
Safe-Harbor
This press release contains statements (such as projections regarding future performance) that are forward-looking as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's web site and prior SEC filings contain various disclosures and RISK FACTORS (incorporated herein by reference) and should be read before any investment decision.
Contact:
Contact:
Thursday, January 15, 2009
FFGO - Back In Play?
Some of you may recall our posts regarding FFGO back in the early summer. The stock rose from $.0001 to a high of $.0009 on huge volume and investor interest. The stock has now settled back down to the $.0001 level with no bid.
Volume has returned to this stock and one might wonder if a run is in the cards again. With penny stocks, history does tend to repeat itself. FFGO should prove no different in this regard as the SEC filings have returned in earnest. SEC filings are positive when dealing with a $.0001 a stock as long as they don't start with the letter "S".
FFGO might fester around the $.0001 area for a few days or a week, but when you least expect it the buyers will far out number the sellers and the stock will take off.
FFGO should be a stock worth watching going forward.
Volume has returned to this stock and one might wonder if a run is in the cards again. With penny stocks, history does tend to repeat itself. FFGO should prove no different in this regard as the SEC filings have returned in earnest. SEC filings are positive when dealing with a $.0001 a stock as long as they don't start with the letter "S".
FFGO might fester around the $.0001 area for a few days or a week, but when you least expect it the buyers will far out number the sellers and the stock will take off.
FFGO should be a stock worth watching going forward.
Thursday, January 8, 2009
SOFN - SoftNet Technology Corp - Huge Run Under Way
SOFN surged 100's of percent higher on record volume today. The stock jumped at the open and closed near the high of the day.
This stock should be one to keep on your radar in the coming days. SOFN has regular filings with the SEC, making the comapny transparent. Check here for the filings http://www.pinksheets.com/pink/quote/quote.jsp?symbol=sofn.
Have a green Friday.
This stock should be one to keep on your radar in the coming days. SOFN has regular filings with the SEC, making the comapny transparent. Check here for the filings http://www.pinksheets.com/pink/quote/quote.jsp?symbol=sofn.
Have a green Friday.
Monday, January 5, 2009
Stocks To Watch January 6th 2009 - VRGD, MOVT, GNTA
VRGD received significant volume today along with a very positive news release by the company just before mid-day.
Mobile Media Unlimited/Veridigm Shareholder Update
VRGD Returns 14% Common Shares to Treasury LONDON, Jan 05, 2009 (MARKET WIRE via COMTEX) -- Veridigm, Inc. (PINKSHEETS: VRGD) today announced the Board has initiated final preparations for Mobile Media Unlimited, Inc. to be traded as a public company. Veridigm, Inc. (DE) will be name changed to Mobile Media Unlimited Holdings, Inc. (DE) in due course.
The Veridigm Board of Directors and MMU Advisors welcomes incoming Chairman, Chief Executive Officer Anthony Sasso effective Jan 01 2009.
Veridigm President Gary Freeman stated: "We have gone to extraordinary lengths to ensure that the Veridigm entity is up to date in all areas of previously unpaid taxation and that Veridigm is in good standing. This arduous task was necessary for the caliber of MMU clients who require qualifying 'means tests,' as well as long overdue Veridigm housekeeping in preparation for Y/E 2008 consolidated auditing and re filing for OTC BB listing status. Simultaneously, MMU's investors garnered control of a 'to be named' secondary US public company which will be utilized for alternative MMU financed projects, proprietary database research and analysis tools, licensing & branding of applications to 3rd parties, joint ventures & other miscellaneous investments that do not immediately qualify as MMU/Veridigm core competencies."
Manny J. Shulman, managing partner of Shulman and Associates LLC who advises Mr. Sasso, MMU & Veridigm, commented: "We are now satisfied that the criteria and qualifications of Veridigm are habitable for the MMU deal. Veridigm has just effected common stock cancellations to its treasury of 40,111,000 or 14.6% shares of common stock. We have formally closed Veridigm's Regulation D 504 offering as of 12/31/08 and irrevocably cancelled all outstanding Reg D 504 exemption legal opinions, Blue Sky exemptions and previously issued 504 shares are no longer exempt from registration. The Company is reporting a not inconsequential & wholly unexplainable differential between its free trading common share count issued and outstanding as reported by CEDE & Co/DTCC and its common share NOBO/OBO count as reported by S&P as compared to its recent Transfer Agent ledger. We do not foresee an immediate resolution of this suspicious differential and we believe this differential may be responsible for VRGD's recent and extended price and volume volatility."
Mr. Shulman continued: "The Company's equity capital remains 510,000,000 shares authorized. 72% of 100% of the controlling VRGD super voting preferred shares are owned by MMU entities & Mr. Sasso. These preferred shares have no conversion ability to common under present restrictions. The remaining 8% of VRGD preferred shares are now owned by two institutional clients who have no ability to convert to common under present restrictions. For more information about MMU's unique business platform please visit www.mmusms.com."
NOTICE: To existing "odd lot" minority shareholders of Veridigm, Inc. common shares: pertaining only to shareholders owning less than a "round lot." These shareholders may receive a purchase proxy solicitation offer or similar solicitation in due course.
The stock should continue to receive attention, and the stock could very well see more price appreciation from these levels.
MOVT rose 300% on Monday fueled by unprecedented buying pressure. The low share structure could equate to more upward movement with continued volume. MOVT is a stock to watch going forward.
GNTA surged 102% on the press release posted below. This stock could head higher again tomorrow. Keep your eyes on it for a quick trade.
Genta Summarizes Phase 2 Activity & Receives Orphan Drug Designation in Gastric Cancer for Tesetaxel, a Leading Oral Taxane i...
Genta Incorporated (OTCBB: GNTA) announced today that the Company has received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel, the latest addition to Genta’s oncology product portfolio, has been granted designation as an “Orphan Drug” for treatment of patients with advanced gastric cancer. Orphan drug status provides for a period of marketing exclusivity, certain tax benefits, and an exemption from certain fees upon submission of a New Drug Application. As a late Phase 2 agent, the Company believes tesetaxel is the leading oral taxane currently in clinical development.
In the completed Phase 2 study, 35 patients with advanced gastric cancer were treated with tesetaxel at doses ranging from 27 to 35 mg/m2 once every three weeks. All patients had received extensive prior treatment, having failed a combination regimen that included cisplatin plus 5-fluorouracil or Xeloda®, and all but 2 patients had received a third chemotherapy drug with this regimen. Final intent-to-treat analysis, including all patients enrolled in the study, showed that 5 patients achieved a partial response, 2 patients achieved a partial response unconfirmed by CT scan, and 14 patients achieved stable disease, for an overall major response rate of 20% and a disease-control rate of 60%. The most serious adverse reaction was Grade 3-4 neutropenia, which occurred in 57% of patients. Six patients failed to complete the first course of treatment. Five patients died on study from differing causes that included intestinal perforation, pneumonia, hepatic failure, hemorrhagic shock, and rapid disease progression. One patient withdrew before receiving the first treatment dose.
“These response data for tesetaxel in a critically ill patient population show clinical activity at levels that are at least comparable to studies with other taxanes,” said Dr. Raymond P. Warrell, Jr., Genta’s Chief Executive Officer. “Based on these data, we have consulted extensively with international experts and will be defining a global registration path for tesetaxel as a 2nd-line treatment for patients with advanced gastric cancer. FDA designation as an Orphan Drug provides important assistance in the clinical development process.” About Tesetaxel Tesetaxel is a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. However, both prototype agents suffer from serious safety issues, particularly hypersensitivity reactions related to intravenous infusions that are occasionally fatal and that require careful premedication and observation. Other prominent side-effects of this drug class include myelosuppression (low blood counts) and peripheral neuropathy (disabling nerve damage).
With administration as an oral capsule, tesetaxel was developed to maintain the high antitumor activity of the taxane drug class while eliminating infusion reactions, reducing neuropathy, and increasing patient convenience. The oral route also enables development of novel schedules that may expand dosing options when tesetaxel is used alone or in combination with other anticancer drugs. Preclinically, tesetaxel has demonstrated substantially higher activity against cell lines that were resistant to paclitaxel and docetaxel, since acquired resistance is not mediated by the multidrug-resistant p-glycoprotein.
As a late Phase 2 oncology product, tesetaxel has demonstrated anticancer activity in its initial clinical trials, and the drug has not been associated with the severe infusion reactions that are linked with other taxanes. Moreover, unlike other oral taxanes, nerve damage has not been a prominent side effect of tesetaxel. Thus, the drug offers substantial opportunities to improve patient convenience, safety, and anticancer activity. More than 250 patients worldwide have been treated with oral tesetaxel in Phase 1 and Phase 2 clinical trials.
About Genta Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
Safe Harbor This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words “potentially”, “anticipate”, “could”, “calls for”, and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with: the Company’s ability to obtain necessary regulatory approval for Genasense® from the U.S. Food and Drug Administration (“FDA”); the safety and efficacy of the Company’s products or product candidates; the Company’s assessment of its clinical trials; the commencement and completion of clinical trials; the Company’s ability to develop, manufacture, license and sell its products or product candidates; the Company’s ability to enter into and successfully execute license and collaborative agreements, if any; the adequacy of the Company’s capital resources and cash flow projections, the Company’s ability to obtain sufficient financing to maintain the Company’s planned operations, or the Company’s risk of bankruptcy; the adequacy of the Company’s patents and proprietary rights; the impact of litigation that has been brought against the Company; and the other risks described under Certain Risks and Uncertainties Related to the Company’s Business, as contained in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.
Mobile Media Unlimited/Veridigm Shareholder Update
VRGD Returns 14% Common Shares to Treasury LONDON, Jan 05, 2009 (MARKET WIRE via COMTEX) -- Veridigm, Inc. (PINKSHEETS: VRGD) today announced the Board has initiated final preparations for Mobile Media Unlimited, Inc. to be traded as a public company. Veridigm, Inc. (DE) will be name changed to Mobile Media Unlimited Holdings, Inc. (DE) in due course.
The Veridigm Board of Directors and MMU Advisors welcomes incoming Chairman, Chief Executive Officer Anthony Sasso effective Jan 01 2009.
Veridigm President Gary Freeman stated: "We have gone to extraordinary lengths to ensure that the Veridigm entity is up to date in all areas of previously unpaid taxation and that Veridigm is in good standing. This arduous task was necessary for the caliber of MMU clients who require qualifying 'means tests,' as well as long overdue Veridigm housekeeping in preparation for Y/E 2008 consolidated auditing and re filing for OTC BB listing status. Simultaneously, MMU's investors garnered control of a 'to be named' secondary US public company which will be utilized for alternative MMU financed projects, proprietary database research and analysis tools, licensing & branding of applications to 3rd parties, joint ventures & other miscellaneous investments that do not immediately qualify as MMU/Veridigm core competencies."
Manny J. Shulman, managing partner of Shulman and Associates LLC who advises Mr. Sasso, MMU & Veridigm, commented: "We are now satisfied that the criteria and qualifications of Veridigm are habitable for the MMU deal. Veridigm has just effected common stock cancellations to its treasury of 40,111,000 or 14.6% shares of common stock. We have formally closed Veridigm's Regulation D 504 offering as of 12/31/08 and irrevocably cancelled all outstanding Reg D 504 exemption legal opinions, Blue Sky exemptions and previously issued 504 shares are no longer exempt from registration. The Company is reporting a not inconsequential & wholly unexplainable differential between its free trading common share count issued and outstanding as reported by CEDE & Co/DTCC and its common share NOBO/OBO count as reported by S&P as compared to its recent Transfer Agent ledger. We do not foresee an immediate resolution of this suspicious differential and we believe this differential may be responsible for VRGD's recent and extended price and volume volatility."
Mr. Shulman continued: "The Company's equity capital remains 510,000,000 shares authorized. 72% of 100% of the controlling VRGD super voting preferred shares are owned by MMU entities & Mr. Sasso. These preferred shares have no conversion ability to common under present restrictions. The remaining 8% of VRGD preferred shares are now owned by two institutional clients who have no ability to convert to common under present restrictions. For more information about MMU's unique business platform please visit www.mmusms.com."
NOTICE: To existing "odd lot" minority shareholders of Veridigm, Inc. common shares: pertaining only to shareholders owning less than a "round lot." These shareholders may receive a purchase proxy solicitation offer or similar solicitation in due course.
The stock should continue to receive attention, and the stock could very well see more price appreciation from these levels.
MOVT rose 300% on Monday fueled by unprecedented buying pressure. The low share structure could equate to more upward movement with continued volume. MOVT is a stock to watch going forward.
GNTA surged 102% on the press release posted below. This stock could head higher again tomorrow. Keep your eyes on it for a quick trade.
Genta Summarizes Phase 2 Activity & Receives Orphan Drug Designation in Gastric Cancer for Tesetaxel, a Leading Oral Taxane i...
Genta Incorporated (OTCBB: GNTA) announced today that the Company has received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel, the latest addition to Genta’s oncology product portfolio, has been granted designation as an “Orphan Drug” for treatment of patients with advanced gastric cancer. Orphan drug status provides for a period of marketing exclusivity, certain tax benefits, and an exemption from certain fees upon submission of a New Drug Application. As a late Phase 2 agent, the Company believes tesetaxel is the leading oral taxane currently in clinical development.
In the completed Phase 2 study, 35 patients with advanced gastric cancer were treated with tesetaxel at doses ranging from 27 to 35 mg/m2 once every three weeks. All patients had received extensive prior treatment, having failed a combination regimen that included cisplatin plus 5-fluorouracil or Xeloda®, and all but 2 patients had received a third chemotherapy drug with this regimen. Final intent-to-treat analysis, including all patients enrolled in the study, showed that 5 patients achieved a partial response, 2 patients achieved a partial response unconfirmed by CT scan, and 14 patients achieved stable disease, for an overall major response rate of 20% and a disease-control rate of 60%. The most serious adverse reaction was Grade 3-4 neutropenia, which occurred in 57% of patients. Six patients failed to complete the first course of treatment. Five patients died on study from differing causes that included intestinal perforation, pneumonia, hepatic failure, hemorrhagic shock, and rapid disease progression. One patient withdrew before receiving the first treatment dose.
“These response data for tesetaxel in a critically ill patient population show clinical activity at levels that are at least comparable to studies with other taxanes,” said Dr. Raymond P. Warrell, Jr., Genta’s Chief Executive Officer. “Based on these data, we have consulted extensively with international experts and will be defining a global registration path for tesetaxel as a 2nd-line treatment for patients with advanced gastric cancer. FDA designation as an Orphan Drug provides important assistance in the clinical development process.” About Tesetaxel Tesetaxel is a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. However, both prototype agents suffer from serious safety issues, particularly hypersensitivity reactions related to intravenous infusions that are occasionally fatal and that require careful premedication and observation. Other prominent side-effects of this drug class include myelosuppression (low blood counts) and peripheral neuropathy (disabling nerve damage).
With administration as an oral capsule, tesetaxel was developed to maintain the high antitumor activity of the taxane drug class while eliminating infusion reactions, reducing neuropathy, and increasing patient convenience. The oral route also enables development of novel schedules that may expand dosing options when tesetaxel is used alone or in combination with other anticancer drugs. Preclinically, tesetaxel has demonstrated substantially higher activity against cell lines that were resistant to paclitaxel and docetaxel, since acquired resistance is not mediated by the multidrug-resistant p-glycoprotein.
As a late Phase 2 oncology product, tesetaxel has demonstrated anticancer activity in its initial clinical trials, and the drug has not been associated with the severe infusion reactions that are linked with other taxanes. Moreover, unlike other oral taxanes, nerve damage has not been a prominent side effect of tesetaxel. Thus, the drug offers substantial opportunities to improve patient convenience, safety, and anticancer activity. More than 250 patients worldwide have been treated with oral tesetaxel in Phase 1 and Phase 2 clinical trials.
About Genta Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
Safe Harbor This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words “potentially”, “anticipate”, “could”, “calls for”, and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with: the Company’s ability to obtain necessary regulatory approval for Genasense® from the U.S. Food and Drug Administration (“FDA”); the safety and efficacy of the Company’s products or product candidates; the Company’s assessment of its clinical trials; the commencement and completion of clinical trials; the Company’s ability to develop, manufacture, license and sell its products or product candidates; the Company’s ability to enter into and successfully execute license and collaborative agreements, if any; the adequacy of the Company’s capital resources and cash flow projections, the Company’s ability to obtain sufficient financing to maintain the Company’s planned operations, or the Company’s risk of bankruptcy; the adequacy of the Company’s patents and proprietary rights; the impact of litigation that has been brought against the Company; and the other risks described under Certain Risks and Uncertainties Related to the Company’s Business, as contained in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.
Thursday, January 1, 2009
ZLNK - a good way to start the new year
ZLNK has risen dramatically the last few weeks as the shell has come under new ownership. ZLNK ran a few years back to the $.035 range on nice volume, but it was a two- three day run. This time around ZLNK has been slowly creeping up and posting nice solid gains on a consistent basis.
Recent trading activity seems to indicate that the share structure is just liquid enough to provide adequate trading, while any uptick in demand for shares and this stock could soar to new highs.
The company is also undergoing a name change that hopefully will provide shareholders with a company that will produce results and continued share appreciation. ZLNK is a stock to watch in 2009.
Recent trading activity seems to indicate that the share structure is just liquid enough to provide adequate trading, while any uptick in demand for shares and this stock could soar to new highs.
The company is also undergoing a name change that hopefully will provide shareholders with a company that will produce results and continued share appreciation. ZLNK is a stock to watch in 2009.
KDSC - a remarkable rally
KDSC surged to new highs early this week after coming under intense accumulation. The stock has seen its value rise from $.0007 to $.012 in the month of December. For anyone holding shares here it has been quite a money making stock.
The question now is how much longer, and how much higher, can this run take KDSC shareholders? After a pull back on the last trading day of the year KDSC should continue higher in the short term, although the volume on the 31st was intense, almost as high as the first big volume day in December. Be wary of continued selling pressure.
But if the seller is done than the stock should resume its run.
The question now is how much longer, and how much higher, can this run take KDSC shareholders? After a pull back on the last trading day of the year KDSC should continue higher in the short term, although the volume on the 31st was intense, almost as high as the first big volume day in December. Be wary of continued selling pressure.
But if the seller is done than the stock should resume its run.
Subscribe to:
Posts (Atom)
Posts
